We then examined the extent of T-cell infiltration and activation (Fig. 5) in the OVA vaccine (containing OVA peptide, imiquimod and IL-2) and CD3xTRP1 double therapy, as well as its impact on innate immune cells (Fig. 6) in both B16F10 and KPC3-TRP1 tumor models. This evidence concerns the gene IL2 and neoplasm.